NervGen Pharma Corp.
NGENF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4 | $3 | $3 | $5 |
| G&A Expenses | $2 | $4 | $3 | $2 |
| SG&A Expenses | $2 | $4 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $6 | $6 | $6 | $7 |
| Operating Income | -$6 | -$6 | -$6 | $0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | -$3 | $2 | -$9 |
| Pre-Tax Income | -$4 | -$9 | -$4 | -$9 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$9 | -$4 | -$9 |
| % Margin | – | – | – | – |
| EPS | -0.06 | -0.13 | -0.056 | -0.12 |
| % Growth | 53.8% | -132.6% | 53.4% | – |
| EPS Diluted | -0.06 | -0.13 | -0.056 | -0.12 |
| Weighted Avg Shares Out | 73 | 72 | 71 | 70 |
| Weighted Avg Shares Out Dil | 73 | 72 | 71 | 70 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$6 | -$6 | -$6 | -$7 |
| % Margin | – | – | – | – |